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Abstracts
 
In Hong Kong, the government subsidizes over 90% of
the medical costs of a patient admitted to a public hospi-
tal. Economic information on new drugs is required for
formulary consideration. Ceftazidime is reserved for the
treatment of severe nosocomial infection. Trovafloxacin,
a new antibiotic introduced to Hong Kong, is a potential
alternative of ceftazidime. OBJECTIVE: To compare the
cost-effectiveness of trovafloxacin with ceftazidime in
nosocomial pneumonia (NP) from a hospital perspective.
METHODS: A decision-analytic modeling method was
employed. Clinical data used were adopted from a ran-
domized clinical trial conducted overseas comparing the
two antibiotics in the treatment of NP together with con-
sultation of a local expert panel. Patients either received
IV alatrofloxacin (injectable form of trovafloxacin) 300
mg every 24 hrs or IV ceftazidime 1 g q8h. The success
rate of alatrofloxacin was 74% and 70% for ceftazidime.
Median duration of IV therapy was 6 and 7 days respec-
tively. Alatrofloxacin and ceftazidime were converted to
trovafloxacin PO 300 mg qd and ciprofloxacin PO 750
mg bid, respectively, to complete a 14-day treatment. In
the event of treatment failure, IV gentamicin 80mg q8h
would be added. Economic data were obtained from the
finance office of the authority concerned. Only direct
medical costs were included in the analysis. Sensitivity
analysis was performed to check the robustness of the re-
sults. RESULTS: The direct cost per patient treated was
HK $28,332 in the trovafloxacin group compared with
HK $31,389 for ceftazidime. CONCLUSION: Alatro-
floxacin/ trovafloxacin therapy appears to be slightly more
cost-effective than ceftazidime in the treatment of NP.
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OBJECTIVE:
 
 Economic analysis comparing Coumadin
(C) and generic warfarins with a range of bioavailabilities
in a population of atrial fibrillation patients from a pro-
vincial government payer perspective over one year.
 
METHODS:
 
 Cost-minimization and cost-effectiveness anal-
yses were conducted. A Markov decision analytic model
evaluated generic warfarin products with bioavailabilities
of 
 

 
2% to 
 

 
15% and 
 

 
20% to 
 

 
25% different from
C. Three clinical scenarios were simulated: (1) C only for
a year (2) generic warfarin only for a year and (3) two ge-
neric agents alternating monthly for a year. Bioavailabili-
ties for generic products were translated into INRs.
Costs: Direct medical (hospital, drug, laboratory, physi-
cian fees). Clinical event: medical literature, Bleeds and
Clots. RESULTS: The average total expected annual cost
for C was $1751. The average expected costs for all ge-
neric agents ranged from $1711 to $2154. In the incre-
mental analysis, generic warfarins, one agent only, pre-
scribed for one year, were dominant (i.e., cheaper) than
C. C was dominant when compared to strategies involv-
ing alternating between generic products for a year. Devia-
tion from C for Clots and Bleeds occurred when bioavail-
abilities were 10% for alternating generic regimens.
Incremental cost-effective ratios ranged from $7000–
$32000 per Clot avoided and $30000–$38000 for Bleed
avoided. CONCLUSIONS: Single generic warfarins with
bioavailabilities similar to C had cost savings. Regimens
involving alternating between two generic warfarins that
differ by 20% and 25% associated with excessive costs.
This may lead to additional INR monitoring, dose adjust-
ments and adverse clinical outcomes.
Retrospective Database Analyses R
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OBJECTIVES:
 
 We compared healthcare resource utiliza-
tion (hospitalizations, physician visits, prescriptions) be-
tween users of pravastatin, lovastatin, and simvastatin.
METHODS: Manitoba’s Health Research Database
identified statin users between 95/1/1 and 98/3/31. Inci-
dent users received a first prescription for a statin after
95/4/30; prevalent users had a prescription before 95/5/1.
Statin ‘interacters’ were on 1 prescription for an inter-
acting drug while on a statin (Group A drug’s levels were
increased; Group B drugs increased levels of statins). Wil-
coxon’s ranksum test analyzed differences by statin on
healthcare resource use. RESULTS: 24,555 statin users
(15,148 incident and 9,407 prevalent) were identified.
19,850 (80.8%) individuals took one statin; 16.7% took
two statins. Most common Group A interactions were
with warfarin (9.7%), amitriptyline (4.4%), and imi-
pramine (4.4%); in Group B, itraconazole (10.8%), ome-
prazole (6.7%), and clarithromycin (4.4%) were the
most common. Statin interacters consumed significantly
more healthcare resources than did noninteracters for
both incident and prevalent analyses. New pravastatin
users taking interacting drugs had on average signifi-
cantly fewer hospitalizations (0.85) and physician visits
(19.33), and lower healthcare costs ($3,954) compared
to new users of lovastatin (1.21, 22.03, $5,559) and sim-
vastatin (1.07, 21.21, $4,734). The comparison of preva-
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lent users was only significant between lovastatin and
pravastatin. 
 
CONCLUSION:
 
 Pravastatin is associated with
less healthcare resource utilization in new users, possibly
due to lack of interaction effects. In prevalent users, the
differences were minimized, possibly due to adjustments
in drug and dosage regimens.
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Much of research on the costs of diabetes mellitus has fo-
cused on long-term complications. There are limited data
on the factors associated with acute diabetes-related
events. OBJECTIVE: The goal of this study was to iden-
tify predictors of acute diabetes complications in a man-
aged-care setting. METHODS: Using a retrospective co-
hort design and a database that linked medical claims
and clinical laboratory data, adult members of a New
England health plan with a diagnosis of diabetes mellitus
between January 1, 1994 through June 30, 1998 were
identified. Inpatient admissions with diagnoses consistent
with acute (“short-term”) diabetes complications (repre-
sented primarily by hyperglycemia, hypoglycemia, and
selected infections) were then evaluated, and expressed
on a 3-year basis. Stratified and multivariate logistic re-
gression analyses were employed to determine the influ-
ence of key factors, such as age, gender, mean glycosy-
lated hemoglobin (HbA1c) value, whether the patient
had a diagnosis of cancer, and whether the patient had
long-term diabetes complications, on the risk of inpatient
admission. RESULTS: Of 2,394 patients with diabetes
mellitus, approximately 11% (269) had at least one inpa-
tient stay for an acute complication over 3 years. The risk
of inpatient treatment for short-term complications was
found to increase 22% (odds ratio 1.22, P  0.01) for
every one point increase in HbA1c. In addition, advanc-
ing age (odds ratios of 1.63 and 2.56 for patients 60 to
69 years and 70 years relative to under 50 years, re-
spectively; both P  0.05), long-term complications
(odds ratio 9.39, P  0.01), and cancer (odds ratio 3.13,
P  0.01) all were associated with increasing risk. CON-
CLUSIONS: In clinical practice, we found that poorer
glycemic control, age, and comorbidity are independent
risk factors for acute diabetes complications. Further re-
search is needed to determine whether better risk-factor
management (e.g., control of HbA1c) can reduce the rate
of acute diabetes complications.
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In 1996 the FDA approved donepezil for treatment of
Alzheimer’s patients with symptoms of memory and cog-
nitive loss. A recent study projected that the cost of done-
pezil could be offset by reduced utilization over a two-
year period. OBJECTIVES: The purpose of this study
was to measure use of donepezil among Veteran’s Health
Administration (VHA) patients during FY’98 and the im-
pact on cost. METHODS: Patients diagnosed with
Alzheimer’s disease in five VHA medical centers were
identified and costs for inpatient and outpatient care
were calculated based on Medicare reimbursement rates.
Extended care costs were calculated at $236 per day
(VHA national per diem). Prescription costs were calcu-
lated using VHA Pharmacy Benefit Management prices.
Patients with medical contraindications, those who died
during the study period, and those admitted to an ex-
tended care facility prior to the beginning of the fiscal
year, were excluded from the analysis. Regression analy-
sis was used to measure the association between done-
pezil use and cost while controlling for severity, comor-
bidity, previous hospitalizations, and site. RESULTS:
Donepezil was used by 11% (167) of patients with no
contraindications (N  1484). The regression analyses
indicated donepezil users had higher pharmaceutical
($800, P  0.0001) and outpatient costs ($801, P 
0.006), but lower inpatient (acute plus extended care)
costs ($1542, P  0.10). There was no substantial dif-
ference in total cost ($58, P  0.95). CONCLUSION:
The results support the hypothesis that higher pharma-
ceutical and outpatients costs related to donepezil use are
offset by lower inpatient costs. The extent of the offset
may be greater for the VHA (due to substantial discounts
with drug manufacturers), than would be found in other
health care systems.
 
R4
 
AVAILABILITY OF HIGHLY ACTIVE 
ANTIRETROVIRAL THERAPY ASSOCIATED 
WITH INCREASED SURVIVAL AND LOWER 
COSTS AT A VA MEDICAL CENTER
McCollum M
 
1
 
, Malone DC
 
2
 
, MacWhinney S
 
3
 
, Bessesen M4
1School of Pharmacy, University of Colorado Health Sciences 
Center, Denver, CO, USA; 2College of Pharmacy, University of 
Arizona, Tucson, AZ, USA; 3Department of Preventive 
Medicine and Biometrics, University of Colorado, Health 
Sciences Center, Denver, CO, USA; 4Infectious Disease 
Section, Denver VA Medical Center, Denver, CO, USA
OBJECTIVE: The objective of this study was to compare
survival and costs before and after the availability of
